Adkins Discusses Benefit of Second-line CAR T-Cell Therapy in Large B-Cell Lymphoma
August 4th 2022Sherry Adkins, MSN, ANP-C, discusses the significance of incorporating CAR T-cell therapy regimens, such as lisocabtagene autoleucel, into earlier lines of treatment for patients with relapsed/refractory large B-cell lymphoma.
Oncology APPs, Research Nurses Are Uniquely Poised to Tackle irAE Management in Follicular Lymphoma
July 20th 2022Because immune-related adverse events can be hard to diagnose, patient education and clear avenues of communication with an oncology care team are critical, according to investigators at the 2022 Pan Pacific Lymphoma Conference.
Adding Bispecific Antibody to Natural Killer Cells May Be Effective in Heavily Pretreated Lymphoma
April 11th 2022Patients with heavily pretreated lymphoma experienced promising clinical responses following treatment with the innate cell engager AMF13 plus preactivated and expanded natural killers (NK) cells.
FDA Follow-Up: Utilizing Relatlimab/Nivolumab in Clinical Practice for Metastatic Melanoma
March 25th 2022Oncology Nursing News® speaks with Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, about the significance of the relatlimab/nivolumab approval for patients with unresectable or metastatic melanoma.